2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y₁₂ Receptor Antagonists in the Asia-Pacific Region

Jack WC Tan,1,2 Derek P Chew,3 Muhamad Ali SK Abdul Kader,4 Junya Ako,5 Vinay K Bahl,6 Mark Chan,7 Kyung Woo Park,8 Praveen Chandra,9 I-Chang Hsieh,10 Do Quang Huan,11 Sofian Johari,12 Dafsah Arifa Juzar,13 Byeong-Keuk Kim,14 Cheol Whan Lee,15 Michael Kang-Yin Lee,16 Yi-Heng Li,17 Wael Almahmeed,18 Eric Oliver Sison,19 Doreen Tan,20 Yu-Chen Wang,21 Shiuian Jong Yeh22 and Gilles Montalescot23,24,25

1. National Heart Centre, Singapore; 2. Sengkang General Hospital, Singapore; 3. College of Medicine and Public Health, Flinders University, Adelaide, Australia; 4. Hospital Pulau Pinang, Penang, Malaysia; 5. Kitasato University and Hospital, Tokyo, Japan; 6. All India Institute of Medical Sciences, New Delhi, India; 7. National University Hospital, Singapore; 8. Seoul National University Hospital Internal Medicine, Seoul, South Korea; 9. Medanta – The Medicity, Gurgaon, India; 10. Chang Gung Memorial Hospital, Taoyuan City, Taiwan; 11. Heart Institute of Ho Chi Minh City, Ho Chi Minh, Vietnam; 12. Ripas Hospital, Brunei; 13. Universitas Indonesia, Jakarta, Indonesia; 14. Yonsei University College of Medicine, Seoul, South Korea; 15. Asian Medical Center, University of Ulster, Seoul, South Korea; 16. Queen Elizabeth Hospital, Hong Kong, China; 17. National Cheng-Kung University Hospital, Tainan, Taiwan; 18. Cleveland Clinic Abu Dhabi, United Arab Emirates; 19. University of the Philippines-Philippine General Hospital, Manila, Philippines; 20. Khoo Teck Puat Hospital, Singapore; 21. China Medical University Hospital, Taichung City, Taiwan; 22. Taipei Medical University, Taipei, Taiwan; 23. Sorbonne University, Paris, France; 24. ACTION Study Group, France; 25. Pitié-Salpêtrière Hospital (AP-HP), Paris, France

Abstract
The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y₁₂ inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y₁₂ inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed.

Keywords
P2Y12 inhibitors, Asia-Pacific, acute coronary syndrome, consensus, aspirin, bleeding

Disclosure: This work was funded through the Asian Pacific Society of Cardiology by unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbis Neich, Boehringer Ingelheim and Pfizer, and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from AstraZeneca; and support for travel to meetings for the study or otherwise from Medtronic; and support for travel to meetings for the study or otherwise from Medtronic. SJ reports honorarium from Medtronic; and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Menarini; and support for travel to meetings for the study or otherwise from Menarini; and support for travel to meetings for the study or otherwise from Menarini. CC reports consulting fee from Asian Pacific Society of Cardiology; grants/grants pending from Daiichi Sankyo. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbis Neich, Boehringer Ingelheim and Pfizer, and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Medtronic; and support for travel to meetings for the study or otherwise from Medtronic. SJ reports honorarium from Medtronic; and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Menarini; and support for travel to meetings for the study or otherwise from Menarini. CC reports consulting fee from Asian Pacific Society of Cardiology; grants/grants pending from Daiichi Sankyo. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbis Neich, Boehringer Ingelheim and Pfizer, and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Medtronic; and support for travel to meetings for the study or otherwise from Medtronic. SJ reports honorarium from Medtronic; and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Menarini; and support for travel to meetings for the study or otherwise from Menarini. CC reports consulting fee from Asian Pacific Society of Cardiology; grants/grants pending from Daiichi Sankyo. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbis Neich, Boehringer Ingelheim and Pfizer, and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Medtronic; and support for travel to meetings for the study or otherwise from Medtronic. SJ reports honorarium from Medtronic; and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Menarini; and support for travel to meetings for the study or otherwise from Menarini. CC reports consulting fee from Asian Pacific Society of Cardiology; grants/grants pending from Daiichi Sankyo. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbis Neich, Boehringer Ingelheim and Pfizer, and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from Medtronic; and support for travel to meetings for the study or otherwise from Medtronic. SJ reports honorarium from Medtronic; and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and travel/accommodation expenses paid to institution from The Meeting Lab. GM reports research grants to the institution or consulting/lecture fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Sante, Bayer, Boston-Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Irsidia, Elsevier, Fédération Française de Cardiologie, Frequence Medicale, ICAN, Lead-Up, Medtronic, Menarini, MSD, Pfizer, Quantum Genomics, Sanofi, SCOR global life, Servier and WebMD. All other authors have no conflicts of interest to declare.

Acknowledgement: Medical writing support was provided by Ivan Olegario of MIMS Pte Ltd.

Received: 20 October 2020 Accepted: 4 November 2020 Citation: European Cardiology Review 2021;16:e02. DOI: https://doi.org/10.15420/ecr.2020.40

Correspondence: Jack Wei Chien Tan, National Heart Centre, 5 Hospital Dr, Singapore 169669, Singapore. E: jack.tan.w.c@singhealth.com.sg

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
The management of acute coronary syndrome (ACS) varies across the Asia-Pacific region. In particular, there is significant heterogeneity regarding the use of reperfusion techniques and pharmacological management. For example, thrombolysis is commonly used for reperfusion in China, India and parts of South-East Asia, whereas percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are more common in Japan, Korea, Taiwan, Australia and New Zealand.

Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin is generally recommended for at least 1 year following an ACS, or longer for patients with a high ischaemic/low bleeding risk. However, there is considerable variation in DAPT duration across Asia and a one-size-fits-all approach based on Western guidelines may not be appropriate for Asian populations. For example, genetic polymorphisms (i.e. polymorphisms affecting CYP2C19 function) associated with a slower rate of bioactivation of clopidogrel have a substantially higher prevalence in Asian people (29–60%) than Caucasian people (15%). Furthermore, the ‘East Asian paradox’ results in a different benefit–risk profile, where the risk of ischaemic events is lower, and bleeding higher, than Western populations, despite higher average on-treatment platelet reactivity. Nevertheless, data generated from Asian patients are limited and rarely incorporated into major international guidelines.

Newer oral therapies have been developed offering faster onset, more potent platelet inhibition and lower response variability than clopidogrel. Ticagrelor, a cyclo-pentyl-triazolo-pyrimidine, has a reversible, direct-acting mechanism of action that is not impacted by CYP2C19 polymorphisms and prasugrel, a thienopyridine prodru, is less susceptible to CYP2C19 polymorphisms than clopidogrel. We aim to summarise key evidence and provide recommendations on the use of P2Y12 inhibitors in Asian patients.

**Methods**

The Asian Pacific Society of Cardiology (APSC) convened a panel of 22 experts from 13 countries in Asia-Pacific with clinical and research expertise in the use of P2Y12 inhibitors, to develop consensus statements on the use of these class of drugs in ACS patients in the Asia-Pacific region. The experts were members of the APSC who were nominated by national societies and endorsed by the APSC consensus board. After a comprehensive literature search, with particular focus on Asian-centric studies, selected applicable articles were reviewed and appraised using the Grading of Recommendations Assessment, Development, and Evaluation system, as follows:

1. High (authors have high confidence that the true effect is similar to the estimated effect).
2. Moderate (authors believe that the true effect is probably close to the estimated effect).
3. Low (true effect might be markedly different from the estimated effect).
4. Very low (true effect is probably markedly different from the estimated effect).

The available evidence was then discussed during two consensus meetings. Consensus statements were developed during these meetings, which were then put to an online vote. Each statement was voted on by each panel member using a three-point scale (agree, neutral or disagree). Consensus was reached when 80% of votes for a statement were agree or neutral. In the case of non-consensus, the statements were further discussed using email, then revised accordingly until the criteria for consensus was reached.

**Results and Discussion**

The efficacy and safety of ticagrelor was demonstrated in the Study of Platelet Inhibition and Patient Outcomes (PLATO), which enrolled more than 18,500 patients with an ACS. The risk of cardiovascular (CV) death, MI or stroke with ticagrelor decreased by 16% compared with clopidogrel after 12 months, with benefit being observed within 30 days and accruing throughout the study period. Notably, ticagrelor reduced the risk of both CV death and recurrent non-fatal MI versus clopidogrel.

The PEGASUS-TIMI 54 study subsequently demonstrated a benefit when extending ticagrelor-based DAPT for up to 3 years. No difference in PLATO- or TIMI-defined major bleeding was observed between ticagrelor or clopidogrel in the PLATO study, but non-CABG-related and TIMI-defined major bleeding was significantly increased in PLATO and PEGASUS-TIMI 54, respectively. Ticagrelor was also associated with an increased risk of dyspnoea.

No interaction between Asian/non-Asian ethnicity and efficacy was observed in PLATO. However, the overall event rate was higher in Asian patients, despite a similar bleeding risk. Southeast Asian patients also appeared to experience higher rates of ischaemic events and bleeding than East Asian patients.

Two randomised but underpowered studies, PHILO and TICA KOREA, compared ticagrelor versus clopidogrel in Asian patients. The risk of bleeding and ischaemic events was increased among East Asian patients with ACS from Japan, Taiwan, and South Korea in PHILO. Likewise, in TICA KOREA, the incidence of clinically significant bleeding was significantly higher with ticagrelor versus clopidogrel among Koreans hospitalised for ACS with planned invasive management, while the incidence of CV death, MI, or stroke was also numerically higher in the ticagrelor arm.

TRITON-TIMI 38 compared prasugrel with clopidogrel in patients with an ACS scheduled to undergo PCI; prasugrel reduced the risk of CV death, MI or stroke by 19% compared with clopidogrel, but the incidence of non-CABG-related TIMI major and life-threatening bleeding were significantly increased. As a result, a reduced 5 mg dose is indicated for patients aged ≥75 years or with body weight <60 kg, and prasugrel is contraindicated for those with a history of stroke or transient ischaemic attacks.

The PRASFIT-ACS study on Japanese patients with ACS undergoing PCI is the only randomised trial comparing the outcomes with prasugrel and clopidogrel in an exclusively Asian population. Notably, patients were administered markedly lower doses of prasugrel (20 mg loading/3.75 mg daily maintenance dosing), yet the incidence of CV death, MI or stroke was reduced by 23% at 24 weeks without significantly increasing non-CABG-related major bleeding. While the reduced risk of ischaemic events was not statistically significantly different, the result was comparable with the TRITON-TIMI 38 trial, although follow-up was shorter.

Only one randomised head-to-head comparison of prasugrel and ticagrelor has been performed – the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. In this open-label study the risk of CV death, MI, or stroke was 36% higher with ticagrelor than prasugrel at 1 year (9.3% versus 6.9%;
The European guidelines note switching from clopidogrel to prasugrel to Asian patients with an ACS are necessary.

**ST-elevation Acute Coronary Syndrome**

**Statement 1.** A 12-month duration of therapy for ticagrelor (180 mg loading and 90 mg twice-daily maintenance dose) and prasugrel (60 mg loading and 10 mg daily) are effective and safe in the prevention of adverse cardiovascular events among patients with ST-elevation MI (STEMI) and are recommended in patients who are undergoing primary PCI. Level of evidence: High. Level of agreement: 100% agree, 0% neutral, 0% disagree.

**Statement 2.** If aspirin and clopidogrel are introduced early in thrombolysis, a switch to ticagrelor should be considered the next day or after 8 hours. Level of evidence: High. Level of agreement: 90.9% agree, 9.1% neutral, 0% disagree.

Both ticagrelor and prasugrel significantly reduce the risk of CV death, MI or stroke in patients with an ST-elevation ACS (STE-ACS) versus clopidogrel. However, ticagrelor and prasugrel have not been extensively studied in Asian patients with STE-ACS, so the use of clopidogrel should not be disregarded.

Antiplatelet therapy should be initiated upon diagnosis of STE-ACS, ideally before or while a patient is being transported to the hospital for primary PCI, in the absence of contraindications (e.g. severe bleeding). Prehospital administration of ticagrelor (i.e. in transit) to patients presenting with an STE-ACS is possible, but does not offer significant benefits beyond a reduced risk of stent thrombosis. Aspirin (300 mg or 325 mg loading dose and 75 mg or 81–100 mg maintenance dose) should be initiated for all STE-ACS patients prior to or at hospital presentation.

For patients initially managed using thrombolysis, US and European guidelines recommend administering clopidogrel immediately, because ticagrelor was administered 24 hours after a STE-ACS in the PLATO study. The European guidelines note switching from clopidogrel to prasugrel or ticagrelor may be considered after 48 hours for patients who receive fibrinolysis and subsequently undergo PCI.

No significant differences in the rate of TIMI major bleeding after 30 days in patients have been observed in STEMI patients treated with ticagrelor or clopidogrel after undergoing fibrinolysis in an approximately 8-hour/next-day timeframe. Likewise, rates of major bleeding were similar after 12 months, indicating that early switching from clopidogrel to ticagrelor after fibrinolysis is feasible. The use of prasugrel after fibrinolysis for STEMI has not been well studied, so no recommendation is made.

**Non-ST-elevation Acute Coronary Syndrome**

**Statement 3.** Ticagrelor (180 mg loading and 90 mg twice daily maintenance dose) is recommended in patients with non-ST-elevation ACS (NSTE-ACS) in patients receiving an early invasive strategy (<12 hours), pre-treatment may not be mandated. Level of evidence: High. Level of agreement: 100% agree, 0.0% neutral, 0.0% disagree.

**Statement 4.** Prasugrel (60 mg loading and 10 mg daily) is recommended only in patients who have undergone percutaneous coronary intervention. In countries where a reduced loading or maintenance dose is approved, a reduced dose may be considered. Pre-treatment is not recommended. Level of evidence: High. Level of agreement: 100% agree, 0% neutral, 0% disagree.

**Statement 5.** Unless bleeding risk is high, a minimum of 6 months of DAPT is recommended to reduce ischaemic risk in NSTE-ACS. Level of evidence: Moderate. Level of agreement: 86.4% agree, 4.5% neutral, 9.1% disagree.

This consensus statement recommends the use of P2Y₁₂ inhibitors as part of DAPT as a cornerstone intervention for NSTE-ACS (Figure 2), in a similar manner to Western guidelines. The efficacy and safety profile of ticagrelor in patients with NSTE-ACS is consistent with the overall PLATO study population. While a study in Chinese patients with NSTE-ACS undergoing PCI suggested that doubling the ticagrelor loading dose may achieve faster onset of platelet inhibition without an increase in adverse events, this is unlikely to be associated with a clinically meaningful benefit and is inconsistent with the approved ticagrelor label.
The efficacy and safety of prasugrel was only investigated in patients who underwent PCI in TRITON-TIMI 38, and the approved indication has been limited accordingly. Reduced prasugrel dosing (20 mg loading/3.75 mg daily maintenance dosing) has demonstrated improved efficacy compared with clopidogrel in Japanese patients with ACS without significantly increasing non-CABG-related major bleeding, supporting lower indicated dosing in some Asian countries.

Prasugrel pre-treatment prior to invasive procedures is not recommended because of the increased risk of bleeding without reducing the risk of ischaemic events.

A net clinical benefit is expected for all patient groups with at least 6 months of DAPT after an ACS. However, for patients with a high risk of bleeding, the reduced risk of ischaemic events needs to be weighed against the risk of bleeding after 6 months. Furthermore, as pointed out by some panelists, the DAPT study evaluated a treatment duration of at least 12 months.

### Bleeding Risk

**Statement 6.** There is no specific bleeding risk calculator recommended for use in Asian populations.

Level of evidence: Very low.

Level of agreement: 95.5% agree, 4.5% neutral, 0.0% disagree.

**Statement 7.** Ticagrelor or prasugrel in combination with aspirin should be considered as first-line for NSTE-ACS patients at high risk of ischaemia, unless patient has prior history of bleeding or is above 85 years old. Adjust the duration of therapy based on bleeding risk.

Level of evidence: Low.

Level of agreement: 72.8% agree, 0.0% neutral, 13.6% disagree.

### Figure 2: Treatment Algorithm for Patients with NSTEMI

- Ischaemia-guided strategy:
  - Ticagrelor†
  - Clopidogrel†
  - Prasugrel is not recommended

- Early coronary angiography/early invasive strategy:
  - First choice: ticagrelor†
  - Second choice: prasugrel†
  - Third choice: clopidogrel†

- Follow-up antiplatelet therapy:
  1. Aspirin indefinitely
  2. Discontinue ticagrelor or clopidogrel 5 days, and prasugrel 7 days, before CABG for patients undergoing revascularisation
  3. Ticagrelor/prasugrel (or clopidogrel as second choice) for up to 12 months

Prasugrel is not indicated for medically treated patients with ACS. The risk of bleeding with prasugrel has also been overestimated compared with ischaemic risk in Asian patients. However, other studies have suggested there is an increased risk of major bleeding versus clopidogrel in East Asian patients. The risk of bleeding with prasugrel has also been reported to be higher than for clopidogrel in Korean patients. The risk of any bleeding has been reported as being comparable between ticagrelor and prasugrel in East Asian patients. Therefore, duration of therapy should be based on a perceived on-going net clinical benefit.

No increase in the risk of bleeding or ischaemic events has been observed in patients administered ticagrelor or prasugrel versus clopidogrel alongside a PPI. However, PPI administration is associated with lower clopidogrel active metabolite levels and ex vivo-measured platelet inhibition.

Bleeding complications may also be reduced with the use of a transradial access during PCI. A 2020 meta-analysis that included 18 randomised controlled trials (n=21,669) found that among patients with ACS who have undergone PCI, transradial access decreased the risk of major bleeding by 38% (p<0.001) compared to a transfemoral route. Radial access was also associated with a 25% lower risk of all-cause mortality (p=0.002). Both results were consistent across subgroups except in those that used bivalirudin as an anticoagulant, wherein no benefit was seen for major bleeding or mortality.
DAPT should not be stopped within 4 weeks of stenting unless it is for critical surgery. The ischaemic versus bleeding risk in patients treated with DAPT undergoing surgery must be weighed during pre-surgery discussions between the cardiologist and the proceduralist.

The Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved label states that ticagrelor should be stopped for up to 5 days prior to elective surgery.3,10

While the European Society of Cardiology 2017 guidelines recommend stopping treatment up to 3 days prior to surgery based on the results of the ONSET/OFFSET study, the panel does not support this recommendation because it is based on a single study.3,56 Clopidogrel and prasugrel treatment should be stopped 5 and 7 days before surgery, respectively.3

Switching Antiplatelet Therapy

Statement 11. Clinicians must evaluate reasons for de-escalation and weigh these against the risk of a possible ischaemic event. If de-escalation is necessary, this should be delayed for as long as possible (at least 1 month, but preferably >3 months after the ACS event) as risk of ischaemic events in revascularised patients decreases over time.
Level of evidence: Low.
Level of agreement: 86.4% agree, 13.7% neutral, 4.5% disagree.

Statement 12. Regardless of time frame, reloading is required when switching from ticagrelor or prasugrel to clopidogrel unless there is on-going bleeding.
Level of evidence: Very low.
Level of agreement: 81.9% agree, 4.5% neutral, 13.6% disagree.

DAPT should be continued for a minimum of 12 months, unless contraindicated or not tolerated.2,3 De-escalation (change from ticagrelor or prasugrel to clopidogrel) may be required due to major bleeding, ambiguity surrounding dose requirements for elderly patients/patients with low body weight using prasugrel, or cost.51,53

De-escalation of ticagrelor or prasugrel to clopidogrel may reduce the risk of bleeding without compromising efficacy.51 However, observational data from Asian patients have suggested that de-escalating DAPT in the absence of platelet-function-testing-guided clopidogrel dosing may increase the risk of ischaemic events without reducing bleeding risk.38,51,53,55

If de-escalation to clopidogrel is necessary, de-escalation should be delayed as long as possible, preferably until >3 months after an ACS, and avoided <1 month after the event,56 because of the time-dependent decrease in the risk of ischaemic events following an ACS.

Data from patients who de-escalate DAPT is limited and a consensus on a de-escalation strategy has not been reached in the literature.

To guide practice despite the lack of strong evidence, the panel consensus is to consider a 600 mg loading dose of clopidogrel when de-escalating from ticagrelor to clopidogrel, irrespective of time from ACS. However, directly de-escalating to a 75 mg daily maintenance dose of clopidogrel is reasonable when de-escalation is due to bleeding.57

Long-term Versus Short-term Dual Antiplatelet Therapy

Statement 13. The standard duration of DAPT is 12 months after an ACS. Extension of DAPT beyond 1 year may be considered for high ischaemic-risk patients, such as those with high-risk stent anatomy, complex coronary anatomy or additional risk factors (e.g. diabetes). Clinicians must evaluate both ischaemic and bleeding risk.
Level of evidence: High.
Level of agreement: 85.5% agree, 0.0% neutral, 4.5% disagree.

Continuing DAPT with clopidogrel beyond 12 months has been shown to decrease the risk of ischaemic events, including CV death, among high-risk patients with a history of MI versus aspirin alone, but is associated with an increased risk of major bleeding.54 Similar outcomes when continuing DAPT with ticagrelor (60 or 90 mg) beyond 12 months were reported in the PEGASUS-TIMI 54 trial, although there was no significant increase in the rate of fatal bleeding or intracranial haemorrhage.54 The FDA and EMA licensed the use of ticagrelor 60 mg from 12–36 months because of its comparable efficacy but lower risk of bleeding versus a 90-mg dose.51,55 DAPT using ticagrelor 60 mg beyond 12 months has also demonstrated a benefit compared with placebo in patients with concomitant multivessel disease or diabetes.51,55

Genotyping, CYP2C19 Polymorphisms and Platelet Function Testing

Statement 14. Due to the lack of positive prospective trials in Asian patients, the routine use of point-of-care platelet function testing to guide decisions in antiplatelet therapy is not recommended.
Level of evidence: Very low.
Level of agreement: 100% agree, 0.0% neutral, 0.0% disagree.

Patients with a CYP2C19 poor metaboliser phenotype may not achieve adequate platelet inhibition with the CYP2C19-dependent prodrug clopidogrel.5 In contrast, ticagrelor and prasugrel are not dependent on CYP2C19 bioactivation,5 but differences in bioactivation alone do not fully account for the reduced risk of ischaemic events with ticagrelor versus clopidogrel.51

CYP2C19 polymorphism-guided antiplatelet prescribing may improve clinical outcomes for patients with ACS and offers a cost-effective approach to treatment.62–64 Point-of-care platelet function testing may also act as a surrogate marker for CYP2C19 polymorphisms for patients administered clopidogrel.65 Nonetheless, despite the high prevalence of CYP2C19 polymorphisms in the Asia-Pacific region, routine use of genotype-guided DAPT is not recommended because of the lack of prospective randomised trials performed in the Asia-Pacific region demonstrating a clinical benefit, though further research is warranted.5,65,66

Special Populations

Statement 15. Ticagrelor has been shown to be effective and safe among specific populations (diabetes, elderly and chronic kidney disease [CKD]) with ACS.
Level of evidence: Moderate.
Level of agreement: 89.9% agree, 9.1% neutral, 0.0% disagree.
Caution and clinical judgment must be exercised when using DAPT in patients with comorbidities associated with an increased risk of ischemic events and/or bleeding, such as diabetes or CKD, and in elderly patients (age >75 years). No dose adjustment is required for ticagrelor. A reduced 5 mg daily dose of prasugrel is required for patients weighing <60 kg and prasugrel is not recommended for patients aged ≥75 years.2,4-6

Future Directions

Spontaneous major bleeding and bleeding associated with urgent invasive procedures remain concerns for patients administered DAPT following an ACS. In particular, the antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. A candidate reversal agent is PB2452 (PhaseBio Pharmaceuticals), a monoclonal antibody fragment that binds ticagrelor, is under investigation and has demonstrated immediate and sustained reversal of the antiplatelet effects of ticagrelor in a phase I study.1,7

Efforts to prospectively investigate the efficacy and safety of CYP2C19 polymorphism-guided antiplatelet prescribing in Asia, and subsequent cost-effectiveness analyses, would be welcomed given the economic considerations that drive antiplatelet prescribing in the region.

Limitations

The breadth of the literature on the role of ticagrelor, prasugrel, and clopidogrel in ACS is diverse and these consensus recommendations are not exhaustive and are based on the best available evidence at the time of publication. The consensus statements are not intended to replace clinical judgement. Furthermore, the use of P2Y₁₂ inhibitors in patients receiving oral anticoagulants due to concomitant AF was not discussed, and is discussed in another consensus document.

Conclusion

When managing Asian patients who have had an ACS with DAPT, there are different considerations compared with those for Western populations. While data from Asian populations comparing outcomes with ticagrelor, prasugrel, and clopidogrel are limited, there is evidence to suggest that ticagrelor or prasugrel should be preferred over clopidogrel for most patients with ACS, particularly those who have undergone PCI. The decision on duration of DAPT – including the need to de-escalate, stop or continue therapy beyond 12 months – should be individualised, considering both the ischaemic and bleeding risk for each patient. □
ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283–93. https://doi.org/10.1016/s0140-6736(09)62391-7.

36. Chen IC, Lee CH, Fang CC, et al. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: a multicenter randomized double-blind pilot study: a meta-analysis of randomized trials. J Chin Med Assoc 2016;79:521–30. https://doi.org/10.1016/j.jcma.2016.02.010. PMID: 27239810.

37. Lee CH, Cheng CI, Kan Yang YH, et al. Ticagrelor versus clopidogrel and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan. Circ J 2018;82:747–56. https://doi.org/10.1253/circj.CJ-17-0532. PMID: 29808474.

38. Kim C, Shin DK, Hong SJ, et al. One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: from Korean health insurance review and assessment data. J Cardiol 2019;73:191–9. https://doi.org/10.1016/j.jcard.2018.08.005. PMID: 30770337.

39. Park KH, Jeong MH, Ahn Y, et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful recanalization; from Korea Acute Myocardial Infarction Registry – National Institute of Health Int J Cardiol 2016;215:193–200. https://doi.org/10.1016/j.ijcard.2016.04.044. PMID: 27282530.

40. Wang HY, Li Y, Xu XM, et al. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl) 2018;131:2097–211. https://doi.org/10.4103/camj.camj_306_16. PMID: 29024300.

41. Wu B, Lin H, Tao TG, et al. Ticagrelor versus clopidogrel in East Asian acute myocardial infarction patients: a nationwide randomized trials. J Comp Eff Res 2018;7:281–91. https://doi.org/10.1007/s40215-017-0074-0. PMID: 29046040.

42. Nishimura K, Waki S, Koike C, et al. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiosc Rev Med 2018;19:689–94. https://doi.org/10.1016/j.carrev.2018.10.006.

43. Yun JE, Kim YJ, Park JJ, et al. Safety and effectiveness of contemporary P2Y12 inhibitors in an East Asian population with acute coronary syndrome: a nationwide multicenter cohort study. J Am Heart Assoc 2019;8:e012076. https://doi.org/10.1161/jaha.119.012076. PMID: 30105070.

44. Kim HS, Kang J, Ahn JH, et al. One-year clinical outcomes in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020;396:1079–89. https://doi.org/10.1016/s0140-6736(20)30947-9. PMID: 32382613.

45. Cusset T, Dehara P, Quilliet J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (Ticagrelor versus the Optimal Antiplatelet Therapy in Patients who have Undergone PCI after Acute Coronary Syndrome) randomized study. Eur Heart J 2017;38:3807–10. https://doi.org/10.1093/eurheartj/ehx275. PMID: 28955135.

46. Lu L, Luo H, Zhang S, et al. Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome. Medicine (Baltimore) 2019;57:3304. https://doi.org/10.1097/md.0000000000033181. PMID: 30508934.

47. Kim HS, Kang J, Han JG, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POTFD-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020;396:1079–89. https://doi.org/10.1016/s0140-6736(20)30779-8. PMID: 32382613.

48. Angiolillo DJ, Rolini F, Storey RF, et al. International expert consensus statement on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017;136:1955–75. https://doi.org/10.1161/circulationaha.117.030164. PMID: 28948738.

49. Udel JD, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2016;37:390–9. https://doi. org/10.1093/eurheartj/ehv442. PMID: 26324537.

50. Bansal S, Bonaca MP, Cornell JH, et al. ticagrelor for East Asian prevention of adverse cardiovascular events in patients with multivessel coronary disease. J Am Coll Cardiol 2018;71:489–96. https://doi.org/10.1016/j.jacc.2017.11.050. PMID: 29940663.

51. Bhattacharjee SK, Banerjee S, Maitra A, et al. Reduced incidence of psychiatric events with ticagrelor in diabetic patients with prior myocardial infarction in REGRESS-1088-54. J Am Coll Cardiol 2016;67:2732–40. https://doi.org/10.1016/j.jacc.2016.03.529. PMID: 27040600.

52. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes with treatment of ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Circ Res 2017;30:120–8. https://doi.org/10.1161/circresaha.117.310621. PMID: 28005498.

53. Zheng L, Yang C, Xiang L, Hao Z. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers 2019;24:517–33. https://doi.org/10.1080/10555469.2019.1634764. PMID: 31051325.

54. Jiang M, You YH. CYP2C19 LOF and GOF-guided antiplatelet therapy in patients with acute coronary syndrome: a cost-effectiveness analysis. Cardiovasc Ther 2017;35:39–46. https://doi.org/10.1177/0142544416673663.

55. Lee JH, Ahn GS, Lee JW, et al. Switching from prasugrel to clopidogrel based on cytochrome P450 2C19 genotyping in East Asian patients stable in an acute coronary syndrome. Platelets 2016;27:301–7. https://doi.org/10.3109/09537282.2015.1058075. PMID: 26505624.

56. Su VR. Using pharmacogenetic testing or platelet reactivity testing to tailor antiplatelet therapy: are Asian different from Caucasians? Eur Cardiol 2013;13:102–4. https://doi.org/10.1016/j.eucar.2013.03.004. PMID: 23694635.

57. Sibbing D, Aridi A, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in patients with recent coronary intervention. J Cardiovasc Risk 2019;26:1251–37. https://doi.org/10.1016/j.jcrv.2019.03.033. PMID: 31202349.

58. Bansal S, Bansal A, Bhat S, et al. Using pharmacogenetic testing or platelet reactivity testing to tailor antiplatelet therapy: are Asians different from Caucasians? Eur J Cardiovasc Prev Rehab 2019;26:1251–37. https://doi.org/10.1177/1024368219850340. PMID: 31310567.

59. Bansal S, Bansal A, Bhat S, et al. Using pharmacogenetic testing or platelet reactivity testing to tailor antiplatelet therapy: are Asians different from Caucasians? Eur J Cardiovasc Prev Rehab 2019;26:1251–37. https://doi.org/10.1177/1024368219850340. PMID: 31310567.

60. Bansal S, Bansal A, Bhat S, et al. Using pharmacogenetic testing or platelet reactivity testing to tailor antiplatelet therapy: are Asians different from Caucasians? Eur J Cardiovasc Prev Rehab 2019;26:1251–37. https://doi.org/10.1177/1024368219850340. PMID: 31310567.